Jedara 5% Cream
Imiquimod Topical
0.0125g
JERASH PHARMACEUTICALS CO. LTD.
| Pack size | 12 sachets (Each containing 250 mg of cream) |
|---|---|
| Dispensing mode | POM |
| Source | JORDAN |
| Agent | PHARMALINK |
| Retail Price | 187.50 AED |
Indications
Jedara 5% Cream is used for:
External genital warts, perianal warts/condyloma acuminata
Adult Dose
Topical/Cutaneous
Anogenital warts
Adult: As 3.75% cream: Apply thinly onto affected area once daily until total clearance or for a Max duration of 8 weeks.
As 5% cream: Apply 3 times weekly (non-consecutive days) for up to 16 weeks.
Perianal warts
Adult: As 3.75% cream: Apply thinly onto affected area once daily until total clearance or for a Max duration of 8 weeks.
As 5% cream: Apply 3 times weekly (non-consecutive days) for up to 16 weeks.
Superficial basal cell carcinoma
Adult: As 5% cream: Apply 5 times weekly (on consecutive days) before bedtime for 6 weeks, assess response 12 weeks after completing treatment.
Actinic keratoses
Adult: As 2.5% or 3.75% cream: Apply unto face or scalp once daily before bedtime for 2 weeks, repeat course after a 2 weeks treatment-free interval, assess response 8 weeks after 2nd course.
As 5% cream: Apply 3 times weekly before bedtime for 4 weeks, repeat for further 4 weeks with a 4-week interval, if necessary; or alternatively, apply 2 times weekly for 16 weeks.
Child Dose
<12 years: Safety and efficacy not established
Renal Dose
Administration
Apply prior to normal sleeping hours and leave on skin for approximately 8 hr; then wash with mild soap and water; non-occlusive dressings such as cotton gauze/underwear may be used in management of skin reactions
Contra Indications
Hypersensitivity
Precautions
Patient with pre-existing autoimmune conditions, reduced haematologic reserve. Organ transplant patients. Not indicated for urethral, intravaginal, cervical, rectal, or intra-anal human papilloma viral disease. Pregnancy and lactation. Patient Counselling Avoid contact with eyes, lips, nostrils and broken skin. Avoid use of occlusive dressing. Avoid exposure to direct sunlight, UV lights, and tanning beds. Monitoring Parameters Assess for reduction in lesion size. Monitor for local skin reactions and signs and symptoms of hypersensitivity.
Lactation: Unknown if distributed in breast milk; use caution
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Imiquimod Topical :
>10%
Application site reaction (33%)
URTI (15%)
Erythema (54-61%)
Erosion (29-31%)
Excoriation/flaking (18-25%)
Edema (12-17%)
Itching (20%)
1-10%
Sinusitis (7%)
Burning (6%)
Headache (5%)
Carcinoma squamous (4%)
Diarrhea (3%)
Bleeding (3%)
Stinging (3%)
Pain (3%)
Eczema (2%)
Induration (2%)
Tenderness (2%)
Irritation (2%)
Back pain (1%)
Fatigue (1%)
Atrial fibrillation (1%)
Viral infection (1%)
Dizziness (1%)
Vomiting (1%)
UTI (1%)
Fever (1%)
Rigor (1%)
Alopecia (1%)
Frequency Not Defined
Headache
Flu-like symptoms
Myalgia
Mechanism of Action
Imiquimod, an immune response modifier, is a Toll-like receptor 7 agonist that activates immune cells. The exact mechanism of action is not yet elucidated. It has no direct viral activity, however, it is effective against viral infection and acts as antitumour agent by induction of interferon-α (IFN-α) and other cytokines.
Note
Jedara 5% 0.0125g Cream manufactured by JERASH PHARMACEUTICALS CO. LTD.. Its generic name is Imiquimod Topical. Jedara 5% is availble in United Arab Emirates.
Farmaco UAE drug index information on Jedara 5% Cream is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.